Abivax Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	4.62	4.62	4.58	11.96
Revenue Growth (YoY)	-	0.83%	-61.68%	-
Gross Profit	4.62	4.62	4.58	11.96
Selling, General & Admin	28.82	28.82	7.49	5.58
Research & Development	103.18	103.18	48.3	47.78
Other Operating Expenses	0	0	13.63	0
Operating Expenses	132	132	69.42	53.36
Operating Income	-127.38	-127.38	-64.84	-41.4
Interest Expense / Income	27.88	27.88	7.02	3.56
Other Expense / Income	-7.51	-7.51	-11.12	-2.51
Pretax Income	-147.74	-147.74	-60.74	-42.45
Net Income	-147.74	-147.74	-60.74	-42.45
Shares Outstanding (Basic)	43	43	19	15
Shares Outstanding (Diluted)	43	43	19	15
Shares Change	-	125.57%	23.53%	-
EPS (Basic)	-3.43	-3.43	-3.18	-2.75
EPS (Diluted)	-3.43	-3.43	-3.18	-2.75
Free Cash Flow	-97.4	-97.4	-54.26	-45.1
Free Cash Flow Per Share	-2.26	-2.26	-2.84	-2.92
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-2756.46%	-2756.46%	-1414.71%	-346.12%
Profit Margin	-3197.14%	-3197.14%	-1325.33%	-354.92%
Free Cash Flow Margin	-2107.66%	-2107.66%	-1183.92%	-377.02%
EBITDA	-119.16	-119.16	-53.23	-38.59
EBITDA Margin	-2578.62%	-2578.62%	-1161.53%	-322.62%
Depreciation & Amortization	0.71	0.71	0.49	0.3
EBIT	-119.87	-119.87	-53.72	-38.89
EBIT Margin	-2593.92%	-2593.92%	-1172.11%	-325.15%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).